Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
The REMAP-CAP study is looking at the best ways to treat adults who are very unwell with lung infections such as severe pneumonia, the flu, or COVID-19, and need care in an intensive care unit (ICU). It's a special type of study that allows doctors to test many different treatments at the same time to see which ones are most effective. This flexible design means the study can quickly adapt to new information, helping doctors make better decisions about care. The goal is to improve how patients recover from these serious illnesses. This study can also quickly adapt to new health crises, like a pandemic, to find treatments for new viruses.
At a glance
What is this study about?
When someone is very ill with a serious lung infection, like severe pneumonia, the flu, or COVID-19, they often need to be looked after in an intensive care unit (ICU). In the ICU, doctors use many different treatments to help patients get better and fight off the infection. While doctors know many treatments are helpful, it's not always clear which combination works best for different people.
This study, called REMAP-CAP, is designed to help doctors figure out the most effective ways to treat these severe lung infections. It's a clever type of study that can test many different treatments all at once. What's more, it's 'adaptive', meaning it can learn from the patients already in the study. This helps the study identify promising treatments faster and direct new patients towards the treatments that seem to be working best.
The main aim is to improve how patients recover from these serious lung infections. It also acts like a flexible research 'platform' that can quickly start looking for treatments if a new widespread illness, like a pandemic, emerges. This means it can rapidly respond to new health challenges and continue to find the best care for patients.
Key takeaways
- Targets severe lung infections like pneumonia, flu, and COVID-19.
- Aims to find the best combinations of existing treatments.
- Can test many treatments at once and adapt quickly.
- Helps improve care for very unwell patients in intensive care.
- Can rapidly respond to new health crises, like pandemics.
Who may be eligible?
Generally, to join the main REMAP-CAP study, you need to be an adult (18 or over) admitted to an intensive care unit (ICU) because of a severe lung infection, like pneumonia, within two days of getting to the hospital. Your doctors would have seen signs of a lung infection and scans showing changes in your lungs. You would also need support for your organs, such as help with breathing or medication to support your blood pressure.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you 18 years old or older?
- Have you been admitted to intensive care for a severe lung infection?
- Did you come to the ICU within 48 hours of being admitted to the hospital?
- Do you need support for breathing or blood pressure in the ICU?
What does participation involve?
If you are asked to join this study, it means your doctors believe you could benefit from it. You would continue to receive the best care for your condition, and the study would involve trying different combinations of existing treatments. This includes various medicines for infection, inflammation, or to prevent blood clots. There are no extra hospital visits or special appointments as part of the study; all monitoring would happen as part of your usual intensive care. The study aims to understand the best treatment approaches and would continue for as long as you need intensive care, with doctors monitoring your progress carefully.
Potential risks and benefits
Locations (408)
- University of FloridaVerified postcodeJacksonville, United States· Recruiting
- Augusta UniversityVerified postcodeAugusta, United States· Not yet recruiting
- University of Illinois HealthVerified postcodeChicago, United States· Recruiting
- Tulane Medical CenterVerified postcodeNew Orleans, United States· Not yet recruiting
- University of MichiganVerified postcodeAnn Arbor, United States· Recruiting
- Memorial Sloan Kettering Cancer CenterVerified postcodeNew York, United States· Recruiting
- Wake Forest Baptist HealthVerified postcodeWinston-Salem, United States· Not yet recruiting
- The Ohio State University Wexner Medical CenterVerified postcodeColumbus, United States· Recruiting
- Oregon Health and Science UniversityVerified postcodePortland, United States· Recruiting
- University of Pittsburgh Medical CentreVerified postcodePittsburgh, United States· Recruiting
- Brown University - Rhode Island HospitalVerified postcodeProvidence, United States· Not yet recruiting
- Canberra HospitalVerified postcodeCanberra, Australia· Recruiting
Common questions
What kind of infections does this study look at?
It looks at serious lung infections like pneumonia, the flu, and severe COVID-19 that require intensive care.
Why is this study different from others?
It can test many treatments at once and adapt quickly, learning from patients already in the study to find better treatments faster.
Will I get special treatment if I join?
You will receive the best possible care, and the study helps doctors choose the most effective combination of existing treatments for you.
Will I have to pay for anything?
No, all care and treatments related to the study are part of your hospital care and involve no extra cost to you.
Can I leave the study if I change my mind?
Yes, you or your family can decide to withdraw from the study at any time. Your medical care will not be affected.
How to find out more
Cameron Green, MSc
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.